Azithromycin and doxycycline for treatment ofBorrelia culture-positive erythema migrans (original) (raw)
References
Burgdorfer, W., Barbour, A. G., Hayes, S. F., Benach, L. J., Grunwaldt, E., Davis, J. P. Lyme disease: a tick-borne spirochetosis? Science 216 (1982) 1317–1319. PubMed Google Scholar
Stanek, G., Satz, N., Strle, F., Wilske, B. Epidemiology of Lyme borreliosis. In:Weber, K., Burgdorfer, W. (eds.): Aspects of Lyme borreliosis. Springer-Verlag, Berlin Heidelberg 1993, pp. 358–370. Google Scholar
Ciesielski, C. A., Markowitz, L. E., Horsley, R., Hightower, A. W., Russell, H., Broome, C. V. The geographic distribution of Lyme disease in the United States. Ann. N. Y. Acad. Sci. 539 (1988) 283–288. PubMed Google Scholar
Asbrink, E., Olsson, I., Hovmark, A. Erythema chronicum migrans Afzelius in Sweden: A study on 231 patients. Zbl. Bakt. Hyg. A 263 (1986) 229–236. Google Scholar
Steere, A. C. Lyme disease. N. Engl. J. Med. 321 (1989) 586–596. PubMed Google Scholar
Preac-Mursic, V., Wilske, B., Schierz, B., Holburger, M., Suss, E.In vitro and_in vivo_ susceptibility of_Borrelia burgdorferi_. Eur. J. Clin. Microbiol. 6 (1987) 424–426. PubMed Google Scholar
Johnson, R. C., Kodner, C., Russell, M., Duray, H. P. Experimental infection of hamsters with_Borrelia burgdorferi_. Ann. N. Y. Acad. Sci. 539 (1988) 258–263. PubMed Google Scholar
Preac-Mursic, V., Wilske, B., Schierz, G., Suss, E., Gross, B. Comparative antimicrobial activity of the new macrolides against_Borrelia burgdorferi_. Eur. J. Clin. Microbiol. 8 (1989) 651–653. Google Scholar
Johnson, E. C., Kodner, C., Russell, M., Girard, D.In vitro and_in vivo_ susceptibility of_Borrelia burgdorferi_ to azithromycin. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 33–38. Google Scholar
Wretlind, B., Johnson, R. C., Hansen, K., Preac-Mursic, V. Antibiotic susceptibility of_Borrelia burgdorferi_ in_in vitro_ and in animal models. Scand. J. Infect. Dis. Suppl. 77 (1991) 143–144. PubMed Google Scholar
Preac-Mursic, V. Antibiotic susceptibility of_Borrelia burgdorferi in vitro_ and_in vivo_. In:Weber, K., Burgdorfer, W. (eds.): Aspects of Lyme borreliosis. Springer-Verlag, Berlin Heidelberg 1993, pp. 301–311. Google Scholar
Massarotti, E. M., Luger, S. W., Rahn, D. W., Messner, R. P., Wong, J. B., Johnson, R. C., Steere, A. C. Treatment of early Lyme disease. Am. J. Med. 92 (1992) 396–403. PubMed Google Scholar
Strle, F., Ružić, E., Cimperman, J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J. Antimicrob. Chemother. 30 (1992) 543–550. PubMed Google Scholar
Strle, F., Preac-Mursic, V., Cimperman, J., Ružić, E., Maraspin, V., Jereb, M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 21 (1993) 83–88. PubMed Google Scholar
Weber, K., Wilske, B., Preac-Mursic, V., Thurmayr, R. Azithromycin versus penicillin V for treatment of early Lyme borreliosis. Infection 21 (1993) 367–372. PubMed Google Scholar
Luft, B. J., Luger, S. W., Rahn, D. W., Dattwyler, R. J., Gadgil, S. D.: Azithromycin and amoxicillin for the treatment of erythema migrans. Preliminary analysis of the double blind trial. In: Proceedings and abstracts of the Vth International Conference on Lyme borreliosis, Arlington, Bethesda, MD: Fed. Am. Soc. Exp. Biol., 1992, abstract no. 56.
Dattwyler, R., Luft, B., Johnson, R., and the Azithromycin Study Group: Serologic response to_Borrelia burgdorferi_ in patients with erythema migrans: the effect of treatment. In: Advances in Lyme borreliosis. Proceedings of the VIth International Conference on Lyme borreliosis, Bologna, Italy, 1994, pp. 136–139.
Steere, A. C., Hutchinson, G. J., Rahn, D. W. A., Sigal, L. H., Craft, J. E., DeSanna, E. T., Malawista, S. E. Treatment of the early manifestations of Lyme disease. Ann. Intern. Med. 99 (1983) 22–26. PubMed Google Scholar
Preac-Mursic, V., Wilske, B., Schierz, G. European_Borrelia burgdorferi_ isolated from humans and ticks. Culture conditions and antibiotic susceptibility. Zbl. Bakt. Hyg. A 263 (1986) 112–118. Google Scholar
Girard, A. E., Girard, D., Retsema, J. A. Correlation of the extravascular pharmacokinetics of azithromycin with_in vivo_ efficacy in models of localized infection. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 49–60. Google Scholar
Foulds, G., Shepard, R. M., Johnson, R. B. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25 (Suppl. A) (1990) 73–82. Google Scholar
McDonald, P. J., Pruul, H. Phagocyte uptake and transport of azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 828–833. PubMed Google Scholar
Marconi, R. T., Garon, C. F. Phylogenetic analyses of the genus_Borrelia_: a comparison of North American and European isolates of_Borrelia burgdorferi_. J. Bacteriol. 174 (1992) 241–244. PubMed Google Scholar
Welsh, J., Pretzman, C., Postic, D., Saint Girons, I., Baranton, G., McClellad, M. Genomic fingerprinting by arbitrary primed polymerase chain reaction resolves_Borrelia burgdorferi_ into three distinct phyletic groups. Int. J. Syst. Bacteriol. 42 (1992) 370–377. PubMed Google Scholar
Peter, O., Bretz, A. G.:In vitro susceptibility of_Borrelia burgdorferi; Borrelia garinii_ and_Borrelia afzelii_ to 7 antimicrobial agents. In: Advances in Lyme borreliosis research. Proceedings of the VIth International Conference on Lyme borreliosis, Bologna, Italy, 1994, pp. 167–170.
Baradaran-Dilmaghani, R., Stanek, G.:In vitro sensitivity of strains of the species_Borrelia burgdorferi sensu stricto, B. afzelii_, and_B. garinii_ against eight antimicrobial chemotherapeutics. In: Program and abstracts of the VIth International Conference on Lyme borreliosis, Bologna, Italy, 1994, abstract no. P078W.